Research programme: irritable bowel syndrome therapy - Melior DiscoveryAlternative Names: MLR-1045
Latest Information Update: 16 Jul 2016
At a glance
- Originator Melior Discovery
- Developer Melior Pharmaceuticals, Inc.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA
- 27 Jun 2008 Preclinical trials in Irritable bowel syndrome in USA (unspecified route)